| Name | Title | Contact Details |
|---|
Blaine Labs is a Santa Fe Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PharmaCord is the key connector between manufacturers, patients, physicians and payors. We provide innovative solutions that drive efficient and rapid access to life saving therapies. At PharmaCord, we help biopharma companies by delivering tailored solutions that alleviate product access hurdles and drive commercial success. Programs are configured with a focus on key stakeholders in a product`s success including physicians, patients and payors. Services are accessed through our CAPS (Centralized Access Patient Services) Center. Rapid uptake and continuation of therapy are the results our clients see. While the name of the company is new, our leadership is not. Over the years our team has provided support to millions of patients and driven commercial success for our client`s products. The leadership team of the company have led the launch of over 40 different products and transitioned dozens of programs spanning a 20-year period.
Since its establishment in 2004, Ray has been leading the global market in digital dentistry by proposing a new standard for dental imaging solutions through state-of-the-art technology.
Welcome to Smiles Dental! Were proud to offer One of a Kind(ness) dentistry at our convenient offices across Washington and Oregon.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.